Articles tagged with Pharmacological Inhibitors
A team of researchers has identified two proteins critical to the destruction of red blood cells by the Oroya fever pathogen. This discovery paves the way for a potential novel therapy against this deadly neglected tropical disease.
Researchers at the University of Plymouth investigate why drugs used to treat other tumours are ineffective against NF2-related schwannoma and meningioma tumours. They explore repurposing clinically tested cancer drugs to target MDR mechanisms, which may lead to effective therapies for patients with these tumours.
A study published in Pediatric Drugs found that children and adolescents with underweight are more likely to discontinue ADHD medication within a year. The researchers also found clear differences in dosage, gender, and age that can affect treatment outcomes.
Researchers at Heidelberg University have discovered a key mechanism for Alzheimer's disease, identifying a neurotoxic protein-protein complex responsible for nerve cell death and cognitive decline. A novel pharmacological inhibitor, FP802, has shown promising results in slowing disease progression.
Indigenous Nigerian food plants, such as Spondias mombin and Xanthosoma sagittifolium, contain flavonoids, alkaloids, terpenoids, and phenolic acids that exhibit anticancer properties. These plants induce apoptosis, inhibit cell proliferation, reduce oxidative stress, and modulate key cellular pathways.
Researchers at Texas Tech University Health Sciences Center have received a $1.94 million grant to study inhibitors that target peripheral neuropathic pain. The project aims to develop novel non-opioid and non-addicting therapies capable of effectively managing chronic pain.
Researchers from the UCLA Health Jonsson Comprehensive Cancer Center are presenting new findings on combination therapies for liver and pancreatic cancers, including a new organoid model for personalized head and neck cancer treatment. Additionally, they are discussing the potential of liquid biopsies for cancer detection and monitoring.
New guidelines support safe and efficient use of JAK inhibitors for treating chronic inflammatory diseases like rheumatoid arthritis, psoriasis, and Crohn's disease. The updated consensus statement considers safety concerns, including cardiovascular disease and cancer risk, to ensure individualized treatment decisions.
Researchers have discovered a new way to stimulate cardiomyocyte proliferation, offering promising results in both human cardiac slices and live animals. This innovative approach targets calcium signaling pathways, potentially transforming the treatment landscape for patients suffering from heart failure.
Researchers aim to identify key mechanisms and molecular targets to prevent tumor progression in Rhabdomyosarcoma patients. The study focuses on the TAK1 protein, which plays a significant role in regulating cell growth, and its potential inhibition as a therapeutic approach.
Scientists from DZNE found that preventing brain inflammation may help treat Alzheimer's disease. The study, published in Immunity, suggests that inhibiting the NLRP3 inflammasome can reduce neuroinflammation and help microglia clear harmful amyloid-beta deposits.
Researchers analyzed 101 Chinese AML samples and identified three subtypes with different molecular characteristics and clinical outcomes. The study also found potential drug combinations that could improve treatment efficacy for subtype S-II&III patients who benefited from allogenic haematopoietic stem cell transplantation.
A study by MedUni Vienna identified a promising therapeutic approach for metabolic liver diseases by targeting fat metabolism inhibition, promoting liver health and reducing liver fat, inflammation and fibrotic remodeling. The approach involves blocking ATGL, an enzyme playing a central role in lipid metabolism.
Researchers found that EZH2 inhibition boosts T-cell immunotherapies' effectiveness by making cancer cells more visible and reducing immunosuppressive regulatory T-cells. This combination therapy showed improved survival rates in mice with lymphomas, suggesting a potential new approach to treating certain cancers.
A clinical study found that an FasL inhibitor, asunercept, led to a faster recovery of COVID-19 patients in eight days compared to 13 days in the control group. The treatment also reduced mortality by about 20%. The study suggests a new therapeutic concept for severe COVID-19.
Researchers at UC Riverside develop a novel method to degrade the Pin1 protein, which is involved in pancreatic cancer development. The 'molecular crowbar' strategy has the potential to target and break down harmful proteins, offering new hope for cancer therapy.
Researchers have discovered a therapeutic approach that shows promise in preclinical models for treating cancers driven by RAS mutations. The study found that tri-complex inhibitors can restore the normal functioning of mutated RAS proteins, aiming to correct the defect that drives cancer growth.
A study analyzed Photosystem I P700 chlorophyll a apoprotein A2 from Chlorella vulgaris, identifying up to 17 distinct bioactivities, including antibacterial, anti-inflammatory, and hypotensive effects. The peptides were found to be non-toxic and likely non-allergenic.
A study from Goethe University Frankfurt reveals that venomous crustaceans, specifically remipede crabs in Mexican cenote caves, contain a variety of toxins with pharmacological potential. The xibalbines peptides effectively inhibit potassium channels and activate signaling pathways involved in pain sensitization.
Huaier has been traditionally used to treat various health conditions, including cancer. Its unique chemical composition and molecular mechanisms of action have shown potent antitumor effects in both in-vitro and in-vivo studies. Further research is needed to fully understand its efficacy and safety in cancer therapy.
Dr. Roger Lo has been awarded a $2 million NIH grant to investigate ways to prevent drug resistance in melanoma treatment and improve the effectiveness of MAPK inhibitors. The team aims to target genetic instability and immune evasion to stabilize the melanoma genome and make it more vulnerable to immune attacks.
Researchers discover 5-HT2A receptor selectively suppresses visual information strength without inhibiting parallel processes. This mechanism regulates the importance attached to incoming information, which could help develop new therapies for psychiatric diseases.
Researchers designed a molecule, MTX-531, that impairs signaling drivers of cancer therapy resistance. In mouse models, MTX-531 led to tumor regressions in multiple head and neck cancers, showing a favorable toxicity profile.
Researchers identified a viable path to developing a novel therapy that would make opioids more effective and safer as a treatment for chronic pain. The study found that selective Hsp90 inhibitors amplified the pain-relieving effects of morphine, reducing tolerance and side effects.
Researchers found that adding an anti-inflammatory drug to immune checkpoint inhibitor therapy resulted in a high response rate of 67% among patients with stage 4 non-small cell lung cancer. The study suggests that reducing chronic inflammation may improve the effectiveness of immunotherapy.
Researchers have made a breakthrough in understanding the GIP hormone's role in regulating insulin levels and weight loss. The study, involving over 500,000 individuals, found that inhibiting the GIP receptor may result in weight loss, while activating it without arresting its signal is crucial.
A new study reveals TNIK's role in various diseases, including fibrosis, cancer, obesity, and Alzheimer's. The protein has been found to drive cancer cell proliferation and treatment resistance, while also regulating metabolic processes.
A team of POSTECH and ImmunoBiome has discovered a dietary-derived bacterial strain, IMB001, that induces nutritional immunity and boosts anti-tumor responses. The strain works by skewing tumor-infiltrating macrophages toward an inflammatory phenotype, leading to increased cell death of rapidly multiplying tumor cells.
Researchers at Kobe University discovered a new gene, FDFT1, responsible for porokeratosis by identifying epigenetic silencing. Patients with localized lesions didn't have inherited damaged copies, leading to a hypothesis that epigenetic changes are the first hit. The findings have implications for treatment and counseling.
The American College of Physicians recommends adding SGLT-2 and GLP-1 agonists to metformin in adults with Type 2 diabetes for improved cardiovascular outcomes. The guidelines prioritize shared decision-making, considering individual patient characteristics and values.
Researchers at the University of Alabama at Birmingham found that blocking Tiam1 activity in spinal neurons abrogates morphine tolerance and hyperalgesia in a mouse model. Prolonged morphine treatment increased activated Tiam1 levels, leading to dendritic spine morphological changes.
A new class of oral medications targeting RAS proteins has shown promising results in preclinical models, potentially offering novel treatment options for nearly all pancreatic tumors. The inhibitors performed well across various models, with minimal impact on normal cells.
MD Anderson researchers presented studies on combination therapies for AML and lung cancer, tumor microbiomes in immunity, and improved HPV screening. Genetic markers predict extended survival with KRAS inhibitors and may identify patients who benefit from novel combinations.
Researchers investigated the mechanism of 2′, 5′-Dihydroxyacetophenone (DHAP) in cytokine storm and found it inhibits inflammatory factors and increases Hdac1 protein stability, alleviating symptoms.
Researchers found that USP1 inhibits cdc42, increases EWS-FLI1 transcriptional output, and simulates Ewing sarcoma growth. A pharmacological inhibitor of USP1 activated cdc42 and inhibited Ewing sarcoma growth.
A novel drug principle has been successfully tested in a mouse model and brain organoids of ALS patients, preventing cell death and improving motor abilities. The discovery of the TwinF interface inhibitor FP802 offers a promising path for fighting ALS and could lead to the development of effective treatments.
Researchers at University of Cincinnati Cancer Center present Phase 2 clinical trial results for a new BTK inhibitor treatment that offers potential for improved efficacy and safety in chronic lymphocytic leukemia. The study also explores the use of IRAK4 inhibitors to target acute myeloid leukemia cells, with promising results.
Researchers at Kyoto University developed a new reactant demonstrating efficacy on proteins with drug-resistant mutations. The new inhibitor, ArNASA, reacts with lysine residues and is highly stable in physiological environments.
Researchers developed novel small molecule inhibitors of CPSF3, a key regulator of transcription termination in ovarian cancer cells. These inhibitors exhibited potent antiproliferative effects and suppressed tumor growth in vivo.
A Phase IIIb study published in the New England Journal of Medicine found that esketamine nasal spray achieved higher remission rates (27.1%) compared to quetiapine extended-release (17.6%) in patients with treatment-resistant depression, indicating its potential as a targeted therapy for this population.
A new study demonstrates that a pill inhibiting a gut enzyme can protect mice from IBD symptoms and preserve intestinal barrier function. The experimental GCPII-inhibiting drug was shown to improve stool consistency, reduce rectal bleeding and inflammation, with no apparent side effects.
Researchers found that inhibiting NLRP3 signaling reduces podocyte senescence, improves lifespan, and slows down healthy podocyte aging in mice. This discovery holds promise for treating age-related kidney diseases.
Researchers at TUM develop an RNA agent for a lung spray that slows macrophage activity, reducing lung inflammation and fibrosis. The active substance RCS-21 is delivered via an inhaler through a special sugar molecule, showing promise in treating acute inflammatory lung damage.
Researchers aim to treat pancreatic ductal adenocarcinoma by targeting amino acid transporter SLC6A14 and compensatory nutrient scavenging mechanisms autophagy and macropinocytosis. Using alpha-methyl-L-tryptophan and hydroxychlorquine, the study seeks to improve therapeutic outcomes in patients with pancreatic cancer.
Researchers from Sahmyook University found that phyllodulcin, a natural sweetener found in hydrangeas, can efficiently inhibit amyloid beta (Aβ) aggregation and dissociate its aggregates in an animal model study. The study suggests that phyllodulcin may be useful in delaying the onset and progression of Alzheimer's disease.
A first-in-human study demonstrates the efficacy of a novel PRMT5 inhibitor, JNJ-64619178, in treating advanced solid tumors. The treatment showed manageable dose-dependent toxicity and achieved preliminary antitumor activity in patients with various cancer types.
A recent study found that PCSK9 inhibitors may impair lung function in some patients, while statins have a protective effect on the brain, increasing hippocampus volume which may reduce dementia and depression risk. The study used genetic data from 340,000 UK Biobank participants.
A new study led by Sandra Casimiro and Luís Costa found a promising molecular target, the RANK signaling pathway, that could be used in combination with standard care to avoid resistance to treatment in metastatic breast cancer. High levels of RANK in cancer cells are associated with resistance to treatment with CDK4/6 inhibitors.
Researchers have found that PD-L1 triggers signaling that intrinsically alters cancer cell phenotype, impacting immune milieu. The study's findings suggest a new approach to treating patients with limited response to immunotherapy.
Researchers at Helmholtz Munich discovered that DHODH inhibitors sensitize cancer cells to ferroptosis by inhibiting ferroptosis suppressor protein-1 (FSP1), not DHODH itself. This finding confirms the crucial role of FSP1 in ferroptosis surveillance and opens up new avenues for developing effective cancer therapies.
A new proof-of-concept Randomized Controlled Trial found tofacitinib effective and safe for Polymyalgia Rheumatica treatment, potentially avoiding steroid use. The study's results suggest a promising alternative treatment option for patients with this condition.
Researchers at the University of Colorado Anschutz Medical Campus have discovered a molecular mechanism contributing to congenital heart defects in infants with Down syndrome. The study found that an abnormal interferon response inhibits key molecular events required for heart development, leading to impaired cardiogenesis.
Researchers found significant decreases in the levels of KRAS, RHOA, RAC1, and CDC42 after PCAI treatment, implicating their role in cancer progression and metastasis. These findings support the potential of PCAIs as potent agents for developing new anticancer therapeutics.
A study by Tokyo Medical and Dental University reveals that chronic kidney disease promotes vascular calcification by altering signaling molecules in blood vessel walls. The researchers identified four microRNAs that target a key pathway driving calcification, providing potential biomarkers and therapeutic targets for both diseases.
A retrospective cohort study found that sodium-glucose cotransporter 2 inhibitors (SGLT2i) significantly reduced the risk of end-stage renal disease, obstructive airway disease, and pneumonia in patients with type 2 diabetes. SGLT2i may be a better alternative to dipeptidyl peptidase-4 inhibitors for extra-glycaemic protection.
A new study by Osaka University researchers demonstrates that the endothelial cell-specific protein Robo4 plays a crucial role in reducing mortality in severe infection. By upregulating Robo4 expression, a drug treatment can decrease vascular permeability and increase survival rates.
Researchers found that MK256 induced differentiation and maturation in leukemia stem cells, inhibiting proliferation of AML cell lines. The study also showed dose-dependent inhibition of the STAT pathway in both in vitro and in vivo studies.
Mandated PDMP use in US states reduced opioid prescriptions by 6.1% but led to a 50.1% increase in heroin-related deaths, according to researchers from the University of Texas at Dallas.
Researchers discovered Empa, an FDA-approved diabetes medication, improved blood vessel function and reduced arterial stiffness in aged male mice. The study suggests SGLT2 inhibition may be a therapeutic tool to delay or reverse vascular aging in humans.
A novel preclinical drug has been developed to inhibit the kinase enzyme Cdk5, which is implicated in neuropsychiatric and neurodegenerative conditions. The drug, 25-106, is brain-permeable and shows promise in altering neurobehavior in mice with anxiety-like behavior.